Itolizumab

DB16207Investigational

Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).

Mechanism: Itolizumab binds to CD6 which modulates T-lymphocyte activation and proliferation. It is an efficacious immunomodulatory compound investigated for treating psoriasis. Currently, the full mechanisms of action are still unclear.
Curator reviewed
Code names: BMAB-600 · EQ001 · T1H

Resolves to

Compound

UNIIXQQ2RHV14NCAS1116433-11-4

Targets

P30203CD6

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Itolizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account